An 8-Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI greater than or equal to 30) With Stage 2 Hypertension.

Trial Profile

An 8-Week Prospective, Multicenter, Randomized, Double-Blind, Active Control, Parallel Group Study to Evaluate the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI greater than or equal to 30) With Stage 2 Hypertension.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Mar 2011

At a glance

  • Drugs Aliskiren/hydrochlorothiazide (Primary) ; Ramipril (Primary)
  • Indications Essential hypertension; Hypertension
  • Focus Therapeutic Use
  • Acronyms ATTAIN
  • Sponsors Novartis
  • Most Recent Events

    • 01 May 2010 Results presented at 25th Annual Scientific Meeting of the American Society of Hypertension.
    • 20 May 2009 Actual patient number (386) added as reported by ClinicalTrials.gov.
    • 20 May 2009 Actual end date (1 May 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top